Wednesday, July 8, 2026

pharma · MPS IIIA · Epidermolysis Bullosa · ABEO

ABEONA THERAPEUTICS

ABEONA THERAPEUTICS is a pharma organization headquartered in Cleveland, USA. It trades on NYSE under ticker ABEO. Primary therapeutic focus areas include MPS IIIA, Epidermolysis Bullosa, Onychomycosis, Epidermolysis Bul

Cleveland, USA HQ
2015 Founded
228 Employees
Public company Type
ABEO · NYSE Ticker
Company details
Status
Public
HQ
Cleveland, USA
Founded
2015
Employees
228
Programs
8
Drugs
3
Patents
0
Clinical program

ABO-102

Phase 2 · small molecule · MPS IIIA

ABO-102 for MPS IIIA is a Phase 2 program (small_molecule) at ABEONA THERAPEUTICS INC. with 1 ClinicalTrials.gov record(s).

← All ABEONA THERAPEUTICS INC. projects Phase 2 small molecule terminated

Internal code ABT-003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ABEONA THERAPEUTICS INC.
Phase
Phase 2
Modality
small_molecule
Indication
MPS IIIA
Status
terminated
Trials
1

Clinical trials